6936.TW Vetnostrum Animal Health Co., Ltd.
- Market cap
- TWD 2.29B
- P/E
- 14.1x
- P/B
- 1.73x
- ROE
- 12.5%
- Dividend yield
- 5.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6936.TW undervalued?
Graham number6936.TW trades 4.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vetnostrum Animal Health Co., Ltd. fundamental analysis
No fundamental analysis for Vetnostrum Animal Health Co., Ltd. yet.
Vetnostrum Animal Health Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vetnostrum Animal Health Co., Ltd.
Vetnostrum Animal Health Co., Ltd. engages in the import, manufacture, and sale of animal medicines, health food, feed additives, and feed. It offers antibiotics, hormonal preparations, topical disinfectants, and drugs for anti-inflammatory, deworming, anti-fungal, antiprotozoal, etc; vitamins, minerals, and amino acids for regular supplementary; and non-medicated feed additives for swine, cattle and sheep, poultry, pet, and aquatic animals. The company was founded in 2012 a…
Full company profileVetnostrum Animal Health Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vetnostrum Animal Health Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.18B | 1.19B | 1.21B | 1.29B | 1.42B | 1.49B |
| Gross Profit | 357M | 353M | 357M | 441M | 452M | 556M |
| Operating Income | 139M | 125M | 111M | 171M | 156M | 208M |
| EBITDA | - | 212M | 192M | 247M | 234M | 280M |
| Net Income | 110M | 107M | 91.6M | 137M | 129M | 166M |
| EPS | 1.66 | 1.61 | 1.38 | 2.06 | 1.77 | 2.28 |
| Balance Sheet | ||||||
| Total Assets | 1.48B | 1.47B | 1.38B | 1.44B | 1.67B | 1.78B |
| Total Liabilities | 515M | 423M | 318M | 308M | 316M | 450M |
| Shareholders' Equity | 967M | 1.05B | 1.06B | 1.13B | 1.35B | 1.33B |
| Cash & Short-term Investments | 79.8M | 91.6M | 104M | 96.5M | 122M | 137M |
| Cash Flow | ||||||
| Operating Cash Flow | 127M | 128M | 235M | 180M | 289M | 126M |
| Capital Expenditure | 42.2M | 22.1M | 15.5M | 30.2M | 25.7M | 27.4M |
| Free Cash Flow | 84.6M | 106M | 220M | 150M | 263M | 98.2M |
| Ratios | ||||||
| ROE | 11.4% | 10.1% | 8.6% | 12.1% | 9.5% | 12.5% |
| ROA | 7.4% | 7.2% | 6.6% | 9.5% | 7.7% | 9.4% |
| Net Profit Margin | 9.3% | 9.0% | 7.6% | 10.6% | 9.1% | 11.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vetnostrum Animal Health Co., Ltd. dividends
- Dividend yield
- 5.35%
- Forward dividend
- 1.51 TWD
- Payout ratio
- 95.2%
- Ex-dividend date
- Jun 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 123M | 1.69 | 95.2% |
| 2024 | TWD 68.9M | 1.04 | 50.5% |
| 2023 | TWD 80.1M | 1.21 | 87.5% |
| 2022 | TWD 82.5M | 1.25 | 77.5% |
| 2021 | TWD 73.7M | 1.11 | 67.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Vetnostrum Animal Health Co., Ltd.
- Insiders 63.60%
- Institutions 5.03%
- Public & others 31.37%
- Shares outstanding 72.8M
- Free float 29.1M
Vetnostrum Animal Health Co., Ltd. company profile
- Company name
- Vetnostrum Animal Health Co., Ltd.
- Ticker
- 6936.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Consumer Defensive
- Industry
- Farm Products
- Employees
- 195
- Fiscal year end
- December
- Address
- No. 290-3, Hsinchu City, Taiwan, 30442
- Phone
- 886 3 621 6688
- Website
- vetnostrum.com
About Vetnostrum Animal Health Co., Ltd.
Vetnostrum Animal Health Co., Ltd. engages in the import, manufacture, and sale of animal medicines, health food, feed additives, and feed. It offers antibiotics, hormonal preparations, topical disinfectants, and drugs for anti-inflammatory, deworming, anti-fungal, antiprotozoal, etc; vitamins, minerals, and amino acids for regular supplementary; and non-medicated feed additives for swine, cattle and sheep, poultry, pet, and aquatic animals. The company was founded in 2012 and is based in Hsinchu City, Taiwan. Vetnostrum Animal Health Co., Ltd. operates as a subsidiary of YungShin Global Holding Corporation.
Vetnostrum Animal Health Co., Ltd. management
3- Wei-Kai ChungChairman & President
- Yi-Fen ChenAccounting Supervisor and Financial & Accounting officer
- Wan-Ting TsaiChief Internal Auditor